PATENT CLAIM ANALYSIS

Application Number: 15767914
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["514", "253040"]

Abstract:
The present invention is directed to a combination therapy involving a selective Bcl-2 inhibitor and a MEK inhibitor for the treatment of a patient in need of such a therapy. The patient in need of the combination therapy is suffering from cancer, such as acute myeloid leukemia.

Claim (Index 20):
The pharmaceutical product of  claim 17  wherein the first composition and the second composition are the same.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 91.0
- Lexical Diversity: 1.5625
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14122779', '14020761', '15116712', '15943229', '14473311']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7971045594441081
- 35 USC 102 Novelty (BERT): 0.5297509964795961
- Combined Prediction Score: 0.7703692031476569
- Mean Citation Score: 294.5926199999999
- Max Citation Score: 321.6076700000001
- Similarity Product: 167.8788059384597

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test